CA
NZ
UK
AU
IND
US
● NeOnc Technologies Holdings is a micro-cap, clinical-stage biopharmaceutical company developing intranasal drug delivery for brain cancers, with lead candidate NEO100 in development for high-grade glioma.
Lipocine Inc. (NASDAQ:LPCN), a penny stock, ticked higher at last closing. Lipocine is a micro-cap, clinical-stage pharmaceutical company built on an oral drug-delivery and prodrug platform, with its only marketed asset, an oral testosterone product, generating small royalties.
● MNKD shares rose 2.53% to $4.06 at last closing, despite broader market weakness following a stronger-than-expected August jobs report that pressured healthcare and biotech stocks broadly.
● Korro Bio is a clinical-stage biotechnology company developing RNA-editing therapeutics for genetic and other diseases.
● Harmony Biosciences is a commercial-stage biopharmaceutical company focused on rare neurological and neuroendocrine diseases.
● Geron Corporation is a commercial-stage biopharmaceutical company with an approved treatment for lower-risk myelodysplastic syndromes, a group of rare bone marrow disorders.
The Ensign Group, Inc. (NASDAQ:ENSG) shares dipped modestly at last closing. Ensign is one of the largest operators of skilled-nursing, post-acute, and senior and assisted-living facilities in the United States, complemented by a real-estate arm, with a growth model centered on acquiring underperforming facilities …
● Coya Therapeutics is a micro-cap, clinical-stage biotechnology company developing regulatory-T-cell, or Treg, based immunotherapies, with lead candidate COYA 302 in development for ALS.
● Clene Inc. is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases, including ALS.
Medtronic (NYSE:MDT) closed at $94.17 at last closing, up 1.15%, extending its post-earnings gains as investors continued to digest the company's strong fiscal first-quarter 2027 report released September 1. Medtronic is a global medical-technology leader that designs, manufactures, and markets device-based therapies across four …
Please wait processing your request...